Safety and effectiveness of ixekizumab in Japanese patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis in real-world use: a post-marketing safety study
These findings are consistent with ixekizumab clinical trial data from other countries, showing the long-term safety and effectiveness of ixekizumab in patients with axial spondyloarthritis under routine clinical care in Japan.
Authors
- Jiasheng Dong
- Hideto Kameda (ORCID: https://orcid.org/0000-0002-4330-5782)
- Chie Yamamoto (ORCID: https://orcid.org/0000-0002-3919-8830)
- Ayako Konomi (ORCID: https://orcid.org/0009-0001-6884-1557)
- Yumiko Nishikawa
- Tetsuya Tomita
Institutions
- Toho University (JP)
- Morinomiya University of Medical Sciences (JP)
- Eli Lilly (Japan) (JP)
Publication Details
- Journal
- Modern Rheumatology
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1093/mr/roaf108
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00